Researchers identify promising cancer drug target in prostate tumors

June 26, 2008

BOSTON--Scientists at Dana-Farber Cancer Institute report they have blocked the development of prostate tumors in cancer-prone mice by knocking out a molecular unit they describe as a "powerhouse" that drives runaway cell growth.

In an article that is being published today as an advanced online publication by the journal Nature, the researchers say the growth-stimulating molecule called p110beta -- part of a cellular signaling network disrupted in several common cancers -- is a promising target for novel cancer therapies designed to shut it down. The report's lead authors are Shidong Jia, MD, PhD, Zhenning Liu, PhD, Sen Zhang PhD, and Pixu Liu, MD, PhD.

The p110beta molecule and a counterpart, p110alpha, are "isoforms" -- slightly different forms - of an enzyme called PI(3)K that is an intense focus of cancer research and drug development. PI(3)K is the linchpin of a cell-signal pathway that responds to growth factor signals from outside the cell.

When activated by growth factor receptors, PI(3)K turns on a cascade of genes and proteins that drives cells to divide and grow. The molecular accelerator is normally kept under control by a tumor-suppressor protein, PTEN, which acts like a brake to curb excess cell growth that could lead to cancer.

Mutations that inactivate PTEN -- in effect releasing the brake on growth signals -- are found in a significant proportion of prostate, breast and brain tumors. The senior authors of the new report, Jean Zhao, PhD, and Thomas Roberts, PhD, previously showed that blocking p110alpha protein inhibits cancerous growth induced by various cancer-causing proteins, such as Her2 and EGFR. With that knowledge in hand, the researchers, in collaboration with pharmaceutical companies, are developing p110alpha blockers.

P110beta, by contrast, was thought to be a relatively insignificant player in tumors. However, "the surprise in this paper is that p110beta has been found to be a bigger player than p110alpha in tumors that result from PTEN loss," noted Zhao. "Now the drug companies, which have been focusing on p110alpha, will have to think about making p110beta inhibitors as well."

Both forms of the p110 molecule have dual tasks: they are involved in responding to insulin signals -- a metabolic function -- as well as relaying growth signals from outside the cell. But the importance of 110beta had been vastly underestimated, the researchers said, for reasons they don't entirely understand.

"We knew that when cells are stimulated with growth factor signals, the activity of p110alpha, but not p110beta, rises rapidly and sharply in triggering excess cell growth," Zhao said. "We speculate that 110beta may be providing a low-level but steady growth stimulus and when PTEN is lost, it becomes an important source of cell proliferation signals."

The new findings stem from experiments in which the scientists disabled the p110beta protein in mice as a way of exploring its normal functions. In one of the experiments, the researchers "knocked out" p110beta in mice that also lacked the PTEN tumor suppressor protein and were therefore highly prone to prostate cancer. Mice that lacked PTEN but had functioning p110beta proteins all developed early prostate cancers by 12 weeks of age. In contrast, the "knockout" mice with no p110beta function remained free of prostate cancer even though the PTEN "brake" had been disabled.

The scientists concluded, as a result, that p110beta becomes a "powerhouse" to drive cancerous cell growth when PTEN function is missing.

In light of the new findings, there is likely to be great interest in finding drugs or other tools to block the p110beta protein in cancers where mutations in PTEN have unleashed the overactive growth signals, said Zhao, who is also an assistant professor of surgery at Harvard Medical School.

The task is made somewhat easier, said Roberts, by the fact that "we know what the inhibitor should look like because of our work on p110alpha inhibitors."

Roberts, who is also a professor of pathology at Harvard Medical School, said that drugs designed to block the p110alpha form are on their way to clinical testing, but he could not predict when p110beta inhibitors might become available for clinical testing.

Dana-Farber Cancer Institute

What You Need To Know About: Prostate Cancer

This booklet is about cancer of the prostate. Each year, more than 186,000 American men learn they have this disease. Prostate cancer is the second most common type of cancer among men in this country. Only skin cancer is more common.
Learning about medical care for prostate cancer can help you take an active part in making choices about your care. This booklet tells about diagnosis and staging, treatment options, tests you may have after treatment and taking part in research studies.

Gleason Grading of Prostate Cancer: A Contemporary Approach
by Mahul B. Amin (Author), David Grignon (Author), Peter A. Humphrey (Author), John R. Srigley (Author)

Featuring more than 300 full-color photomicrographs that represent the entire spectrum of the Gleason grading system, this atlas is the first comprehensive and definitive reference devoted to Gleason grading of prostate cancer. It is written by four eminent authorities in urologic pathology who bring their collective expertise and consensus opinion in Gleason grading. Illustrative case examples from the authors' collections highlight the pitfalls and problems of applying the Gleason grading system to contemporary techniques in pathology.

Histological Typing of Prostate Tumours (WHO. World Health Organization. International Histological Classification of Tumours)
by K.F. Mostofi (Author), I.A. Sesterhenn (Author), C.J. Jr. Davis (Author), L.H. Sobin (Assistant)

This revision of the book originally published in 1980 is the result of a collaboration among scientists from 10 countries. The authors include not only pathologists but also a urologist and a basic scientist. The second edition - containing 146 colour photographs - is considerably more extensive than its predecessor. A number of new entities, unrecognized in 1980, are included: prostatic intraepithelial neoplasia, which is commonly associated with carcinoma and may also be seen in a biopsy for elevated PSA; basal cell carcinoma; small cell carcinoma; paracrine-endocrine elements; variants of carcinoma; and stromal sarcoma. The criteria for the diagnosis of carcinoma have been expanded, including the minimal criteria. The Gleason grading system, based on growth pattern, is presented in...

Role of Prostate-Specific Antigen (PSA) in Pathological Angiogenesis and Prostate Tumor Growth (Cancer Etiology, Diagnosis and Treatments)
by Ravikumar Aalinkeel (Author), Stanley A. Schwartz (Author), B. Bindukumar (Author), Gary J. Smith (Author), Kailash C. Chadha (Author)

Prostate specific antigen (PSA) is a serine protease present in an enzymatically inactive form in human serum at a concentration of nanograms/ml; serum PSA (S-PSA) is used widely as a surrogate marker in the diagnosis and management of prostate cancer (CaP). However, the vast majority of PSA produced in the prostate is secreted as active enzyme into the seminal fluid or is sequestered within the prostate tissue microenvironment. This book examines the role of the prostate-specific antigen in prostate tumour growth.

Prostate Health in 90 Days
by Larry Clapp (Author)

Larry Clapp discovered he had prostate cancer in 1990, and delved into self-healing alternatives to surgery and radiation, and developed a cure for prostrate cancer that he used successfully on himself. This book employs nutrition, massage, herbs, homeopathy and other medical alternatives that can not only cure you but enhance your sex life, and your physical and mental strength.

You Can Beat Prostate Cancer: And You Don't Need Surgery to Do It
by Robert J. Marckini (Author)

The task of choosing the right prostate cancer treatment is daunting. It is further complicated by conflicting information the patient receives from physicians and the Internet. This book is written by a prostate cancer survivor who now runs an internatio

What you need to know about prostate cancer (SuDoc HE 20.3152:P 94/2/2000)
by U.S. Dept of Health and Human Services (Author)

Beating Cancer with Nutrition, book with CD
by Patrick Quillin (Author)

Beating Cancer with Nutrition. Sugar feeds Cancer: diet and supplements can starve tumorsÂ· Nutrition makes chemo and radiation more toxic to the tumor while protecting the patient. Nutrition changes underlying causes of cancer, improving outcome for cancer patients regardless of other therapies. Why Beating Cancer with Nutrition is unique: The book was developed after working with over 500 cancer patients and organizing 3 international symposiums on the subject. The information contained in BCN is both scientifically backed with references and clinically proven in the hospital with patients. This information helps cancer patients to improve quality and quantity of life. BCN had been translated into Japanese and Chinese and is being translated into Korean. BCN had become a home study...

Winning the Battle Against Prostate Cancer: Get the Treatment That is Right for You
by Gerald Chodak (Author)

The range of controversial therapies and treatments for prostate cancer is greater than that of any other cancer affecting men. Many of the current books on prostate cancer suffer from considerable bias promoting one treatment over another without good scientific evidence. Winning the Battle Against Prostate Cancer is an unbiased and up-to-date look at prostate cancer treatments and therapies, resolving the problem of contradictory and incomplete information. Dr. Chodak outlines the pros and cons of all reasonable treatment options, recognizing that men and their families need more than just the facts — they are concerned not only with their survival but also what life will be like after treatment. This book offers empathetic insight into the impact of the disease on day-to-day...